HARTMANN at a glance
HARTMANN is a leading international manufacturer of medical and hygiene products.
In a world where health is becoming an increasingly important matter and is managed more professionally, we offer our customers simple and effective solutions for the benefit of the patients. This is expressed in our brand promise of “Going further for health”. Professional solutions for wound treatment, incontinence hygiene and infection prevention form the core of our portfolio.
In 2017, we employed 10,764 staff worldwide and generated sales of EUR 2,058 million.
The HARTMANN solutions
In line with internal management, the HARTMANN GROUP's business activities are reported on by business segments which are arranged by product range focus, i.e. Wound, Incontinence and Infection Management as well as Other Group Activities, primarily including the activities of the Group companies, KNEIPP, KOB, CMC and NOGE.
In our Wound Management segment, HARTMANN has, among other things, further improved its highly absorbent Zetuvit® Plus, which is intended for wounds with high levels of exudate, and the HydroClean® plus dressing. This was singled out for its innovative absorbing-rinsing-mechanism by the Journal of Wound Care as Most Innovative New Dressing 2017.
Share of total sales by business segment
in EUR million and percent (2017)
on the other, for healthcare personnel this means savings in time and effort spent applying it. And frequently occurring conditions of their musculoskeletal system are thus avoided.
In the Infection Management segment, the primary focus remains on innovations in products for hand and surface disinfection. These are an integral part of a multimodal, holistic concept for the improvement of hand hygiene.
Other Group Activities comprises our activities in cosmetic cotton-wool products, first aid, Kneipp product lines and retail business.
Share of total sales by region
in EUR million and percent (2017)
Shares of regions in total sales of the HARTMANN GROUP (in million euros and as a percentage; discrepancies due to rounding not adjusted).
We are present in over 30 countries with our own sales and manufacturing organisations, but our solutions are available in around 100 countries through a network of distributors. You can find our offices in a number of countries throughout Europe, but we are also present in America, Africa, Asia, and Oceania.
In Germany, the HARTMANN GROUP includes, among others, the companies BODE Chemie/Hamburg, Karl Otto Braun/Wolfstein, Sanimed/Ibbenbüren and Kneipp/Würzburg.
At €138.2 million, EBIT has declined slightly over the previous year. Next to the one-off effect from the LINDOR acquisition, this is largely due to pricing pressure on the markets for medical and healthcare products, as well as higher regulatory spending. However, thanks to an improved financial outcome we have increased the consolidated net income by 4.0%. The dividend remains stable.
|in EUR thousand||2016||2017||Year-on-year
|Sales revenues|| 1,986,450
|Of which outside Germany in %||65.8||66.5||1.1|
|Consolidated net income||90,100||93,704||4.0|
|Net return on sales in %||4.5||4.6||0.4|
|Cost of materials||868,065||873,064||0.6|
|Return on EBIT DA in %||10.6||9.9||-6.1|
tangible and intangible assets
|Return on EBIT in %|| 7.0
|Balance Sheet total||1,329,339||1,431,969||7.7|
|Investments in tangible and
intangible assets 2
|Equity capital and reserves||816,208||854,838||4.7|
|Equity/asset ratio in %||61.4||59.7||-2.8|
|Return on equity in %||11.0
|Net Financial Status||101,955
|Employees as at Dec. 31 1)||10,372||10.764||3.8|
1) Excl. staff on parental leave and PAUL HARTMANN AG Management Board members
2) Excluding investments from acquisitions like goodwill